These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

128 related items for PubMed ID: 8936659

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. [Treatment of Grave's ophthalmopathy with high doses of corticosteroids].
    Cirić J, Zarković M, Stojanović M, Pepenezić Z, Randjelović G, Gligorović M, Trbojević B, Drezgić M, Nesović M.
    Srp Arh Celok Lek; 2000; 128(5-6):179-83. PubMed ID: 11089418
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Randomized, double-blind, placebo-controlled trial of long-acting release octreotide for treatment of Graves' ophthalmopathy.
    Stan MN, Garrity JA, Bradley EA, Woog JJ, Bahn MM, Brennan MD, Bryant SC, Achenbach SJ, Bahn RS.
    J Clin Endocrinol Metab; 2006 Dec; 91(12):4817-24. PubMed ID: 16984988
    [Abstract] [Full Text] [Related]

  • 9. Urinary glycosaminoglycans in Graves' ophthalmopathy.
    Kahaly G, Schuler M, Sewell AC, Bernhard G, Beyer J, Krause U.
    Clin Endocrinol (Oxf); 1990 Jul; 33(1):35-44. PubMed ID: 2401097
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Prednisone and cyclosporine in the treatment of severe Graves' ophthalmopathy.
    Prummel MF, Mourits MP, Berghout A, Krenning EP, van der Gaag R, Koornneef L, Wiersinga WM.
    N Engl J Med; 1989 Nov 16; 321(20):1353-9. PubMed ID: 2519530
    [Abstract] [Full Text] [Related]

  • 13. Effects of octreotide treatment on Graves' ophthalmopathy and circulating sICAM-1 levels.
    Ozata M, Bolu E, Sengul A, Tasar M, Beyhan Z, Corakci A, Gundogan MA.
    Thyroid; 1996 Aug 16; 6(4):283-8. PubMed ID: 8875747
    [Abstract] [Full Text] [Related]

  • 14. Effect of octreotide treatment on Graves' ophthalmopathy.
    Uysal AR, Corapçioğlu D, Tonyukuk VC, Güllü S, Sav H, Kamel N, Erdoğan G.
    Endocr J; 1999 Aug 16; 46(4):573-7. PubMed ID: 10580750
    [Abstract] [Full Text] [Related]

  • 15. Measuring disease activity to predict therapeutic outcome in Graves' ophthalmopathy.
    Terwee CB, Prummel MF, Gerding MN, Kahaly GJ, Dekker FW, Wiersinga WM.
    Clin Endocrinol (Oxf); 2005 Feb 16; 62(2):145-55. PubMed ID: 15670189
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. [The assessment of urinary glycosaminoglycans (GAG) excretion during therapy of patients with progressive Graves' ophthalmopathy].
    Pilarska K, Kulig G, Krzystolik Z.
    Pol Arch Med Wewn; 2001 Feb 16; 105(2):139-44. PubMed ID: 11505748
    [Abstract] [Full Text] [Related]

  • 19. Evaluation of immunological mechanisms mediating thyroid-associated ophthalmopathy by radionuclide imaging using the somatostatin analog 111In-octreotide.
    Moncayo R, Baldissera I, Decristoforo C, Kendler D, Donnemiller E.
    Thyroid; 1997 Feb 16; 7(1):21-9. PubMed ID: 9086565
    [Abstract] [Full Text] [Related]

  • 20. Therapeutic responses to corticosteroids in Graves' ophthalmopathy.
    Chang TC, Kao SC, Hsiao YL, Lu CP, Huang KM, Tzeng SS.
    J Formos Med Assoc; 1996 Nov 16; 95(11):833-8. PubMed ID: 8990770
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.